1. Home
  2. CBIO vs NATH Comparison

CBIO vs NATH Comparison

Compare CBIO & NATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBIO

Crescent Biopharma Inc.

N/A

Current Price

$12.02

Market Cap

389.7M

Sector

N/A

ML Signal

N/A

Logo Nathan's Famous Inc.

NATH

Nathan's Famous Inc.

N/A

Current Price

$100.65

Market Cap

411.8M

ML Signal

N/A

Company Overview

Basic Information
Metric
CBIO
NATH
Founded
2003
1916
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
389.7M
411.8M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
CBIO
NATH
Price
$12.02
$100.65
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$26.67
N/A
AVG Volume (30 Days)
163.9K
38.2K
Earning Date
01-01-0001
05-22-2026
Dividend Yield
N/A
1.99%
EPS Growth
N/A
22.29
EPS
N/A
4.17
Revenue
N/A
$104,201,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$24.07
Revenue Growth
N/A
7.81
52 Week Low
$8.72
$88.00
52 Week High
$17.39
$118.32

Technical Indicators

Market Signals
Indicator
CBIO
NATH
Relative Strength Index (RSI) 56.70 55.05
Support Level $11.88 $100.25
Resistance Level $13.37 $101.71
Average True Range (ATR) 0.91 0.41
MACD 0.10 -0.18
Stochastic Oscillator 53.37 50.00

Price Performance

Historical Comparison
CBIO
NATH

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About NATH Nathan's Famous Inc.

Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.

Share on Social Networks: